137 results about "Papilloma virus" patented technology

The invention relates to the technical field of human papilloma virus detection, in particular to a primer probe combination, a reagent or kit for human papilloma virus nucleic acid detection and application. The purpose of detecting different types is achieved by adding different specific probes, 18 common human papilloma virus DNAs which are internationally recognized to be closely related to cervical cancer can be detected at a time, and HPV16 and HPV18 types are subjected to typing detection. The application provides 6 universal primers (including 4 target primers and 2 internal standard primers) and 19 specific probes (including 18 target probes and 1 internal standard probe), the 4 target primers can amplify DNA of 18 human papilloma viruses, and the 18 probes are specific probes designed for the 18 human papilloma viruses. And meanwhile, by optimizing the primer probe and the reaction liquid, the purpose of detection is achieved.

The invention relates to the technical field of PCR (Polymerase Chain Reaction) detection, and discloses a high-risk human papilloma virus DNA (Deoxyribose Nucleic Acid) multiplex PCR detection kit, which adopts a primer probe group and comprises a PCR mixed solution, a negative reference substance and a positive reference substance, wherein the PCR mixed solution comprises a primer probe group. Female first-stage urine is used as a detection sample, and compared with a cervix uteri sample, sampling is more convenient, the experience feeling is better, and the willingness of female cervical cancer screening can be provided; meanwhile, the content of cervical exfoliated cells in the urine is also increased by using the first-stage urine, and the clinical sensitivity of clinical HPV detection can be remarkably improved by matching with a provided cell enrichment method.

Compositions and methods are provided for treating HPV infections including pre-malignant and cancers. Compounds that specifically bind to the HPV E6 protein and inactivate the protein are disclosed.

The invention refers to the use of PAP-I, a plant ribosome inactivating protein (RIP), or a functional variant thereof for treatment of human papillomavirus (HPV) infection and preventing or treating diseases or conditions associated with HPV infection.

The invention relates to a quadruple TaqMan real-time fluorescent quantitative PCR (Polymerase Chain Reaction) primer group and a probe group for simultaneously detecting cGPV (Complementary Glutathione Virus), MDPV (Minimal Disease Papilloma Virus), MDGPV (Minimal Disease Papilloma Virus) and SBDSV (Sequence Broadcast DSV) and a kit thereof. The sequences of the primer group and the probe group are respectively shown as SEQ ID NO.1-12. The research successfully develops and verifies a multiple TaqMan-MGB real-time fluorescent PCR method capable of simultaneously detecting and distinguishing four important waterfowl parvoviruses (cGPV, MDPV, MDGPV and SBDSV). The method has good specificity, repeatability and high sensitivity. Compared with a conventional PCR method, the multiple detection method has the advantages that the clinical waterfowl parvovirus detection rate is remarkably improved, mixed infection can be effectively recognized, and the clinical diagnosis efficiency is greatly improved.

Methods for treating human papillomavirus (HPV) type 16- or HPV type 18-associated high-grade squamous intraepithelial lesions (HSIL) of the cervix are described

The present disclosure provides 3,7-disubstituted 2-oxo-2H-chromenyl compounds of Formula I or Formula II as inhibitors of helicases, such as SF3 and / or SF6 helicases, and more particularly, for example, CMG helicase and HPV El helicase, useful in treating medical disorders such as cancers or papilloma virus infections, as well as methods of making and using said compounds.

This invention discloses a traditional Chinese medicine composition for treating HPV infection, its preparation, and its uses. The composition comprises the following ingredients in the indicated weight percentages: 10-40 parts of *Hedyotis diffusa*, 10-30 parts of *Smilax glabra*, 10-30 parts of *Hedyotis diffusa*, 10-30 parts of *Paeonia suffruticosa*, 10-40 parts of *Lithospermum erythrorhizon*, 10-30 parts of *Dictamnus dasycarpus*, 10-30 parts of *Radix Paeoniae Rubra*, 10-30 parts of *Cicadae Periostracum*, 10-30 parts of *Astragalus membranaceus*, and 10-30 parts of *Glycyrrhiza uralensis*. It effectively inhibits the replication of human papillomavirus (HPV) nucleic acid, thereby effectively treating cervical HPV infection caused by HPV, as well as infectious skin diseases such as cervical precancerous lesions and condyloma acuminata caused by HPV infection.

The invention relates to the technical field of skin care, and discloses pure plant compound liquid for removing warts and repairing a skin cuticle barrier and a preparation method of the pure plant compound liquid. The compound liquid is prepared by compounding a purslane extract, a brucea javanica extract, a honeysuckle extract, a licorice extract, an aloe extract, hyaluronic acid, glycerin, menthol and deionized water according to specific parts by weight. The preparation method comprises the steps of raw material pretreatment, basic liquid preparation, active ingredient addition, seasoning and homogenization, filtration and sterilization and the like. Whole plant extracts are adopted as core active ingredients, the synergistic effect of resisting viruses, removing warts, resisting inflammation and repairing skin barriers is achieved through scientific compounding, the activity of human papilloma viruses can be efficiently inhibited, wart shedding is promoted, damaged cuticles can be repaired, and skin resistance can be enhanced; the product is free of chemical preservatives and corrosive components, high in safety, small in irritation, suitable for various skin types, simple in preparation process and suitable for industrial large-scale production.

The invention discloses an mRNA (messenger Ribonucleic Acid) quality control product of human papilloma virus as well as a preparation method and application thereof, and belongs to the technical field of in-vitro diagnosis quality control. The method comprises the following steps: chemically synthesizing an HPV E6 / E7 gene DNA sequence, respectively cloning the HPV E6 / E7 gene DNA sequence into a cloning vector to construct a synthetic plasmid template, further preparing a nucleic acid fragment containing E6 / E7 mRNA through in-vitro transcription, carrying out absolute quantification through a digital PCR technology, mixing the nucleic acid fragment with human cervical cancer cell line RNA without any HPV sequence, and screening to obtain the HPV E6 / E7 gene DNA sequence. And the mRNA quality control product with stable structure and accurate value is prepared through a vacuum freeze drying technology. The quality control product can simulate HPV E6 / E7 mRNA in a clinical sample, has comprehensive types, is suitable for accurate evaluation of sensitivity, specificity, precision and other analysis performances of an HPV E6 / E7 mRNA detection kit, provides a key quality control tool for accurate risk stratification of cervical cancer, and is suitable for various detection platforms.

The invention belongs to the field of preparation of high-antibacterial carbon dots, and discloses a high-antibacterial carbon dot, a preparation process and application of the high-antibacterial carbon dot in vaginal gel. The prepared carbon dots are prepared by adopting physical shearing and ultrasonic synergistic pretreatment, then cooperating with microwave gradient energy crushing and stripping, and then performing centrifugation, dialysis purification and vacuum freeze drying, the damage of oxidation or acid treatment to a graphite structure is avoided in the whole process, and the carbon dots have excellent antibacterial and antiviral performance, can effectively inactivate various pathogenic microorganisms, and have good application prospects. Comprise herpes simplex virus, human papilloma virus HPV16, staphylococcus aureus, candida albicans and the like. The invention also optimizes application conditions, is suitable for developing efficient and safe vagina antibacterial gel products, and provides an innovative solution for preventing and treating gynecological infection.

The present invention relates to chimeric papilloma virus L1 proteins and polynucleotides encoding thereof, and also to HPV virus-like particles and the preparation methods thereof. Said chimeric papilloma virus L1 protein comprises an N-terminal fragment derived from L1 protein of the first papilloma virus type, said N-terminal fragment maintains the immunogenicity of the L1 protein of the corresponding type of HPV; and a C-terminal fragment derived from L1 protein of the second papilloma virus type, said L1 protein of the second papilloma virus type has a better expression level and a better solubility compared to the L1 proteins of other HPV types; wherein said chimeric papilloma virus L1 proteins have the immunogenicity of the L1 proteins of the corresponding HPV types. Said chimeric papilloma virus L proteins have better expression amount and solubility for mass production of vaccines.

The invention relates to a method, uses, a system, and a kit for detecting a human papillomavirus (HPV) genotype associated with the development of cervical, oral, or anogenital cancer in a subject and for determining the HPV genotype or genotypes thus detected in the same. Additionally, the present invention relates to uses of direct and / or reverse amplicons or primers generated by multiplex real-time PCR comprising a molecular tag for identifying a marker of human papillomavirus genotypes 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, and / or 68.

The present invention provides a composition comprising a cytidine analog, in particular decitabine or azacitidine. In particular, the present invention provides a composition comprising a cytidine analog, in particular decitabine or azacitidine, which is useful for topical application. The present invention also provides the use of such compositions for medical conditions in the keratinizing and non-keratinizing epithelium / skin, such as the treatment of human papillomavirus (HPV)-related pre-cancerous conditions.

The invention provides a therapeutic papilloma virus mRNA vaccine and application thereof. The invention provides mRNA molecules as shown in SEQ ID NO: 57-89, and the mRNA molecules can enhance T cell activation and immunogenicity, stimulate an organism to generate TH1 type cellular immune response and increase the tumor inhibition rate.

Multiantigenic human papillomavirus (HPV) molecular vaccine constructs for use and treatment of HPV-related disorders and conditions, e.g., HPV molecular vaccines targeting HPV6 and HPV11-associated recurrent respiratory papillomatosis (RRP).

The application belongs to the technical field of detection, and relates to a human papilloma virus detection reagent and application thereof. The human papilloma virus detection reagent comprises human papilloma virus antigen coated magnetic microparticle reagent and alkaline phosphatase labeled human papilloma virus antibody reagent. The human papilloma virus antigen coated magnetic microparticle is sealed by a sealing agent which is mixed by 2-10wt% PEG6000 solution, DB1130 and 0.1-1wt% gelatin solution. The system for detecting human papilloma virus antibody adopted by the application fills the gap of domestic HPV chemiluminescence antibody detection, and has high sensitivity, accuracy and clinical value.

Disclosed herein, inter alia, are acyclic nucleotide analogs and methods of using an acyclic nucleotide analog for treating and / or ameliorating a papillomavirus infection.

The invention relates to the technical field of gene detection kits, in particular to a kit for rapidly detecting human papilloma virus genes, which comprises reagent bottles or tubes containing nucleic acid release liquid, enzyme mixed liquid, primer mixed liquid, a negative quality control product and a positive quality control product, and a packaging box for separating and intensively packaging the reagent bottles or tubes, the kit adopts an LAMP amplification system without a probe, a detection result of the human papilloma virus can be obtained within 10-15 minutes through a fluorescent dye and interpretation equipment, and the kit has the characteristics of high sensitivity, high specificity, simplicity in operation and high detection speed, and can be widely applied to auxiliary diagnosis of the human papilloma virus.

Provided are a composition for treatment and the like of bovine papillomatosis caused by bovine papillomavirus, and a method using the same. Provided are a composition for treatment, amelioration, and / or suppressing the progression of bovine papillomatosis caused by bovine papillomavirus, the composition containing, as an active ingredient, a compound represented by Formula (I) below or a pharmaceutically acceptable salt of the compound; and a method for treating, ameliorating, and / or suppressing progression of, bovine papillomatosis caused by bovine papillomavirus, the method including administering, to a cow, a compound represented by Formula (I) below or a pharmaceutically acceptable salt of the compound:

The present application belongs to the field of biomedical technology, and relates to a human papilloma virus (HPV) infection immune response related detection method and application. The present application provides a new method for detecting HPV infection, which comprises detecting virus load, DC maturation state in peripheral blood, or T lymphocyte subgroups and NK cell surface markers. The present application adopts a combined detection technology of DC cells, T lymphocytes and NK cells, and is used for detecting the immune response state of a host after HPV infection. The present application also provides application of the detection method. The detection method of the present application is simple and clear in result, and can be applied to clinical auxiliary detection and examination of HPV and even cervical cancer, and screening of HPV and even cervical cancer.

A microwave antenna device includes a conductive ground element defining a hole, a conductive elongated element extending through the hole and terminating at a distal end, and one or more dielectric elements. One or more of the dielectric elements electrically insulate the elongated element and the ground element from each other. The microwave antenna device can be configured to radiate microwave energy into surface tissue of the cervix to provide a therapeutic effect in one or more areas of the cervix (e.g., one or more areas of the cervix infected with human papillomavirus (HPV) and / or diagnosed with cervical intraepithelial neoplasia (CIN)), or to produce a correct biological response in one or more such areas. The microwave antenna device can be configured for local non-ablative thermal therapy of surface tissue of the cervix, local ablation of surface tissue of the cervix, and / or cauterization of surface tissue of the cervix.

Disclosed herein is an immunotherapy for human papillomavirus. More particular, disclosed is a therapeutic composition that includes one or more polypeptides that comprise a plurality of epitopes derived from multiple human papillomavirus antigens, which, when used in immunotherapy is capable of eliciting a protective and durable cell mediated immune response, without being limited thereto. Also disclosed are methods of treating or preventing HPV and / or cancer.

Disclosed herein is the use of purified 2-S rimantadine or purified 2-R rimantadine, or a pharmaceutically acceptable salt thereof, for the treatment of cancer and precancerous lesions in a subject in need thereof, including cancer and precancerous lesions associated with papilloma virus.

The present invention provides a primer-probe combination for detecting HPV and / or HPV typing, belonging to the field of human papillomavirus (HPV) detection technology. The primer-probe combination includes one or more of HPV16E7, HPV18E7, HPV31E7, HPV45E7, HPV33E7, HPV35E7, HPV59E6, HPV68E6, HPV58E7, HPV51E6, HPV52E7, HPV56E6, HPV66E6, and HPV39E6, and can distinguish different types of HPV, with good specificity, accuracy, and low detection limit. The present invention uses a digital PCR method (dPCR) to detect the fluorescent signal of each droplet, and calculates the copy number of the target gene fragment in the entire reaction system based on the Poisson distribution principle, so that absolute quantification can be achieved without relying on a standard curve.

The invention relates to the technical field of biology. The invention provides a construction method of an E7 cell model for expressing human papilloma viruses 16 and 18, which comprises the following steps: transfecting exogenous plasmids into TC-1 cells in a culture medium inoculated with the TC-1 cells; the culture medium contains G418 genetics mycin; the exogenous plasmid can be used for stably transforming the HPV18E7. The TC-1-HPV18E7 cell model and the mouse model are successfully constructed, and it is proved that the recombinant strain vaccine LM-HPV18E7 shows a good treatment effect in a mouse model application test. According to the TC-1-HPV18E7 cell model, the application of the cell model based on TC-1 can be expanded, and a foundation is laid for subsequent research and development of bivalent and even multivalent therapeutic vaccines.

The present invention relates to chimeric papilloma virus L1 proteins and polynucleotides encoding thereof, and also to HPV virus-like particles and the preparation methods thereof. Said chimeric papilloma virus L1 protein comprises an N-terminal fragment derived from L1 protein of the first papilloma virus type, said N-terminal fragment maintains the immunogenicity of the L1 protein of the corresponding type of HPV; and a C-terminal fragment derived from L1 protein of the second papilloma virus type, said L1 protein of the second papilloma virus type has a better expression level and a better solubility compared to the L1 proteins of other HPV types; wherein said chimeric papilloma virus L1 proteins have the immunogenicity of the L1 proteins of the corresponding HPV types. Said chimeric papilloma virus L proteins have better expression amount and solubility for mass production of vaccines.

Multi-antigenic human papilloma virus (HPV) molecular vaccine constructs for use and treatment of HPV-associated disorders and pathologies, such as HPV molecular vaccines targeting HPV16-, HPV18-, and HPV-45-associated pathologies.

The present invention relates to a human papillomavirus antigen peptide and its application, belonging to the technical field of immunomedicine. The antigen peptide comprises the amino acid sequence shown in SEQ ID NO.1, or a small peptide having more than 90% similarity to the amino acid sequence shown in SEQ ID NO.1. The above-mentioned human papillomavirus antigen peptide is a new target located in the E7 gene of the HPV16 genome. This target is not expressed in normal human tissues during viral genome expression and can be used as an antigen target for applications in reagents, drugs, or vaccines for the diagnosis, treatment, and prognosis determination of clinical HPV16 / 18 infections or HPV16 / 18-positive tumors such as cervical cancer, esophageal cancer, head and neck cancer, oropharyngeal cancer, anogenital cancer, etc. For example, through adoptive T cell immunotherapy, it may bring new treatment possibilities to patients with advanced recurrent cervical cancer.

The invention discloses gel for resisting genital tract HPV (human papilloma virus) infection and a preparation method of the gel. The gel is prepared from the following components: 15 to 22 percent of poloxamer 407; 0 to 10 percent of poloxamer 188; 0.01 to 0.25 percent of hydroxypropyl methyl cellulose; 0.5%-5% of an acidic buffer agent (the pH value is 3.5-4.0); 2.5 to 12.5 percent of a wetting agent; 0.01 to 0.2 percent of preservative; and pure water. The anti-genital tract HPV infection gel provided by the invention not only can effectively kill and inhibit genital tract HPV viruses, but also has no irritation and anaphylaxis to genital tract mucous membrane epithelial cells, is good in safety, relatively simple in preparation process and controllable in quality, and can be developed as a medicine or a medical instrument product.